Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to

Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan

Net Sales are expected to increase by 31 percent Y-o-Y (down 2.6 percent Q-o-Q) to Rs. 810.3 crore, according to Sharekhan.
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
Australia biz expanded; rebounded strongly in India & EMs: Strides Shasun

In an interview to CNBC-TV18, Shashank Sinha, Managing Director of Strides Shasun spoke about the results and his outlook for the company.
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Border tax counter productive for US, may never happen: Strides

Going forward, the pharma company is going to to focus on its B2C business and the high cash generating verticals, he says.
Q2 has been a comeback quarter for us in EMs: Stides Shasun

In an interview to CNBC-TV18, Shashank Sinha, Group CEO of Strides Shasun spoke about the results and his outlook for the company.
API biz turnaround likely in 6-8 months: Strides Shasun

In an interview to CNBC-TV18, Arun Kumar, Executive VC and MD of Strides Shasun said the company may sell off its API unit after enhancing its value.
Strides Shasun Q1 numbers 10% below estimate: Nirmal Bang

Strides Shasun for the first quarter reported net profit at Rs 41.79 crore and total income stood at Rs 870 crore versus Rs 955 crore quarter on quarter.
Advertisement
Remove Ad
What to expect from Strides Shasun Q1?

CNBC-TV18‘s Ekta Batra talks about what to expect from Strides Shasun‘s numbers today.
Strides Shasun Q1 PAT seen down by 8.9% at Rs 87.6 cr: Religare

Sales are expected to decrease by 4.7 percent Q-o-Q (up 58.3 percent Y-o-Y) to Rs 955.0 crore, according to Religare Research.
See margin growing, Australian biz picking up: Strides Shasun

Third quarter performance was hit due to floods in Chennai but there has been a strong pullback in the last quarter, he said, adding growth in business from regulated markets like Australia and the US have helped, said Arun Kumar, Executive VC & MD at Strides Shasun.
Aim to grow biz at 20-25% CAGR: Strides Shasun

The growth trajectory is very strong going forward and the company has all the necessary engines to grow the business at 20-25 percent CAGR, said Arun Kumar, MD, Strides Shasun.
Advertisement
Remove Ad
See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
Strides Arcolab bets on Agila to drive growth in FY13

Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.

Stride Arcolab targets Rs 2200cr revenue in 2011

Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”
Strides Arcolab Mar qtr PAT seen up at Rs 38.6 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Strides Arcolab March quarter sales are expected to go up by 28.3% at Rs 479.1 crore, year-on-year, (YoY) basis.
Advertisement
Remove Ad
Business to grow Rs 1000cr in FY11: Stride Arcolab

Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.